Digital Therapeutic
Phase 1
Therapeutic Area: Central Nervous System (CNS)
Anchored in external partnership or acquisition
This compound is under investigation.
Boehringer Ingelheim is investigating evidence-based prescription digital therapeutics (PDT). Installed on a smartphone, the PDT is supposed to be prescribed by healthcare professionals as an adjunctive to standard of care therapy to treat the behavioral dimensions of diseases and conditions.
This supports Boehringer Ingelheim’s approach to provide more holistic support for people living with chronic and complex mental health conditions through digital therapeutics.